8-K: Kenvue Reports Q2 2026 Growth, Meets Expectations Amidst Kimberly-Clark Deal

Kenvue Inc. announced its second quarter 2026 financial results, showcasing a third consecutive quarter of net and organic sales growth, with diluted EPS rising 9% to $0.24.

Summary

• Kenvue reported a 3.0% increase in net sales for the second quarter of 2026 compared to the prior year, reaching $3.955 billion.
• Organic sales grew by 1.6%, driven by a 0.9% increase in value realization and a 0.7% increase in volume.
• Diluted Earnings Per Share (EPS) increased by 9% to $0.24, and Adjusted Diluted EPS rose 7% to $0.31.
• Gross profit margin was 58.2%, and Adjusted gross profit margin was 60.2%.
• Operating income margin was 17.7%, and Adjusted operating income margin was 22.1%.
• Net cash from operating activities was $1.2 billion for the six months ended June 28, 2026, up from $1.0 billion in the prior year.
• Free cash flow increased to $1.0 billion for the six months ended June 28, 2026, from $0.8 billion in the prior year.
• The company received FDA approval for Tylenol with Naproxen, a new over-the-counter pain relief product.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with Kenvue demonstrating consistent sales growth and improved EPS, alongside strategic progress on its pending acquisition. The results met or exceeded internal plans, indicating solid operational execution.

Positives

• Achieved third consecutive quarter of net and organic sales growth.
• Net sales increased by 3.0% to $3.955 billion in Q2 2026.
• Organic sales grew by 1.6%, indicating underlying business strength.
• Diluted EPS increased by 9% to $0.24, and Adjusted Diluted EPS by 7% to $0.31.
• Broad-based gains were reported across every segment and region.
• The Self Care segment saw a return to Organic sales growth in the U.S.
• Skin Health and Beauty segment delivered strong organic sales growth of 3.7%, driven by Hair Care and Face Care.
• Essential Health segment showed growth, particularly in Wound Care and Baby Care, with strong eCommerce momentum.

Negatives

• Gross profit margin decreased slightly to 58.2% from 58.9% in the prior year period.
• Adjusted gross profit margin decreased to 60.2% from 60.9%.
• Operating income margin decreased to 17.7% from 18.0%.
• Adjusted operating income margin decreased to 22.1% from 22.7%.
• The year-over-year change in gross and operating margins was impacted by inflation, tariffs, and unfavorable transactional foreign exchange.

Risks

• Inflation and other economic factors, such as interest rate and currency exchange rate fluctuations, as well as existing or proposed tariffs and other constraints on trade.
• Challenges in managing local, regional, or global economic volatility and generating sufficient income and cash flow.
• Ability to maintain satisfactory credit ratings and access capital markets.
• Competition, including technological advances, new products, and intellectual property attained by competitors.
• Challenges inherent in new product research and development, and uncertainty of commercial success for new and existing products.
• Challenges to intellectual property protections, including counterfeiting.
• Manufacturing difficulties or delays, internally or within the supply chain.
• Product efficacy or safety concerns resulting in product recalls or regulatory action.

Future Outlook

Due to the pending transaction with Kimberly-Clark, Kenvue will not be providing forward-looking guidance for future periods.

Management Comments

• "We delivered our third consecutive quarter of net and organic sales growth, with broad-based gains across every segment and region," said Kirk Perry, Chief Executive Officer.
• "We also continued to drive operational efficiencies and increase strategic investment to fuel sustained momentum."
• "Amidst a dynamic consumer and macro environment, our first-half 2026 results met or exceeded our expectations across key metrics, underscoring the strength and resilience of our people, brands, and new strategic plans."
• "Our transformation is firmly on track. We remain focused on disciplined execution and continued business improvement while we work toward completing our value-creating combination with Kimberly-Clark in the fourth quarter of this year."

Industry Context

StockSavvy.ai notes that Kenvue's performance aligns with broader trends in the consumer health sector, which is experiencing steady demand for essential products. The company's focus on organic growth and strategic investments in brands like Zyrtec and Neutrogena demonstrates a commitment to maintaining market share in a competitive landscape, even as it navigates a significant merger.

Comparison to Industry Standards

• Kenvue's organic sales growth of 1.6% in Q2 2026 is a positive indicator, especially when compared to the generally moderate growth rates seen in many mature consumer staples categories.
• The reported gross profit margin of 58.2% is robust and generally higher than many companies in the broader consumer goods sector, reflecting strong brand equity and pricing power.
• The increase in Diluted EPS to $0.24 signifies effective cost management and operational leverage, a key benchmark for profitability in the industry.
• The pending acquisition by Kimberly-Clark is a significant strategic move, positioning Kenvue within a larger entity that may offer greater scale and market influence, a common theme in industry consolidation.

Stakeholder Impact

• Shareholders: The pending acquisition by Kimberly-Clark offers shareholders a cash and stock transaction, subject to closing conditions.
• Employees: The 2026 Restructuring Initiative aims to optimize operations, which could have implications for workforce structure.
• Customers: Continued focus on brand building and innovation, such as the new Tylenol with Naproxen, aims to provide enhanced consumer choices.
• Suppliers: Operational efficiencies and supply chain optimization initiatives may impact supplier relationships and terms.

Next Steps

• Continue execution of the 2026 Restructuring Initiative to optimize operating model, transform supply chain, reduce complexity, and drive operational efficiencies.
• Work towards completing the value-creating combination with Kimberly-Clark in the fourth quarter of 2026.
• Focus on disciplined execution and continued business improvement.
• Launch Tylenol with Naproxen, a new OTC pain relief product, at major U.S. retailers.

Key Dates

Recommendation

Kenvue is demonstrating consistent operational performance with sequential sales and EPS growth, and has achieved key regulatory approval for a new product. However, the pending acquisition by Kimberly-Clark introduces a significant overhang. While the deal is expected to close in Q4 2026, the terms and integration process warrant a 'hold' stance until the transaction is complete and the combined entity's strategy becomes clearer.

Keywords

consumer health, Kenvue, Q2 2026, earnings, sales growth, organic sales, EPS, Tylenol